2025 SABCS Highlights: Advances in ctDNA for Breast Cancer | Dana-Farber Cancer Institute
🛍️ Products Mentioned (1)
Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss important advances in ctDNA and minimal residual disease (MRD) for breast cancer in the neoadjuvant, adjuvant, and advance settings. This research was presented at the 2025 San Antonio Breast Cancer Symposium. For more information about Dana-Farber's Breast Oncology Center, visit https://www.dana-farber.org/cancer-care/treatment/breast-oncology
🎬 More from Dana-Farber Cancer Institute
Understanding Chemo Neuropathy: A Webinar by the Older Adults with GI Cancer Program | Dana-Farber
19 views
Learning About Chronic Lymphocytic Leukemia | Lymph Notes: A Lymphoma Learning Series
112 views
ASCO26: David Reardon, MD Glioblastoma Vaccine | Dana-Farber Cancer Institute
106 views
Society of Gynaecological Oncology Congress 2026: Tara Berman, MD | Dana-Farber Cancer Institute
30 views
ASCO26: Julia Rotow, MD Silevertinib in Lung Cancer | Dana-Farber Cancer Institute
55 views
ASCO26: Atish Choudhury, MD, PhD A-DREAM/Alliance A032101 | Dana-Farber Cancer Institute
38 views